The malignancy risk of thyroid incidentalomas detected by [18F]FDG PET/CT lower than expected: a nationwide observational study in the Netherlands
European Journal of Nuclear Medicine and Molecular Imaging · 2026
DOI: 10.1007/s00259-025-07714-0 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Hannelore I Coerts und 7 weiteren Autor:innen. Beteiligte Einrichtung: Academic Center for Thyroid Disease, Department of Radiology and Nuclear Medicine, Erasmus Medical Centre Rotterdam, P.O. Box 2040, Rotterdam, 3000, …. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Thyroid Neoplasms, Incidental Findings. Die Arbeit nennt 13 Literaturangaben. Gefördert von: KWF Kankerbestrijding.
Abstract (Originalsprache)
BACKGROUND: The widespread use of 18F-fluorodeoxyglucose positron emission tomography/computed tomography ([18F]FDG PET/CT) has led to increased detection of thyroid incidentalomas (TIs). Current guidelines cite malignancy rates of 31–33% for [18F]FDG-positive thyroid nodules, but population-based data remain limited. This study aimed to assess the malignancy risk and cytological distribution of [18F]FDG PET TIs in a nationwide cohort. METHODS: This retrospective observational study analyzed data from the Dutch nationwide pathology databank (Palga) for all patients who underwent thyroid fine-needle aspiration between January 2012 and December 2019, with follow-up until December 2022. Patients were classified as [18F]FDG PET TI based on documentation of [18F]FDG PET positivity in pathology reports. The primary outcome was malignancy risk compared between [18F]FDG PET TI and control groups. Secondary outcomes included distribution across Bethesda System categories and histological subtypes. RESULTS: Among 64,706 patients analyzed, 3,938 (6.1%) underwent fine-needle aspiration for [18F]FDG PET thyroid incidentalomas. [18F]FDG PET TI detection increased 128% between 2012 (n = 281) and 2019 (n = 641). Patients with [18F]FDG PET TIs were older (median 64 vs. 52 years, p < 0.001) and more likely male (30.8% vs. 19.1%, p < 0.001). The overall malignancy rate was significantly higher in [18F]FDG PET TIs compared with controls (19.4% vs. 8.8%, p < 0.001). [18F]FDG PET TIs demonstrated higher proportions of suspicious cytological categories: atypia of undetermined significance (Bethesda III) (13.1% vs. 6.5%), follicular neoplasm (Bethesda IV) (10.2% vs. 4.3%), suspicious for malignancy (Bethesda V) (7.3% vs. 2.9%), and malignant cytology (Bethesda VI) (6.8% vs. 2.1%) (all p < 0.001). Among patients with indeterminate cytology, 36% of Bethesda IV and 29% of Bethesda V cases did not undergo surgery. Papillary thyroid carcinoma was the predominant malignant subtype (52.3%), with no anaplastic carcinomas observed. CONCLUSIONS: This largest population-based study demonstrates that [18F]FDG PET TIs have a malignancy rate of 19.4%, which is lower than the 31–33% cited in current guidelines. The substantial proportion of cytologically suspicious nodules that do not proceed to surgery suggests potential inefficiency in current diagnostic approaches. These findings support more selective FNA strategies and enhanced risk stratification to optimize patient care while minimizing unnecessary interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Academic Center for Thyroid Disease, Department of Radiology and Nuclear Medicine, Erasmus Medical Centre Rotterdam, P.O. Box 2040, Rotterdam, 3000, CA, the Netherlands.
- Department of Radiology and Nuclear Medicine, Utrecht Medical Center, Heidelberglaan 100, Utrecht, 3584 CX, the Netherlands.
- Department of Radiology and Nuclear Medicine, Erasmus MC Cancer Institute, Doctor Molewaterplein 40, Rotterdam, 3015 GD, The Netherlands.
- Academic Center for Thyroid Disease, Department of Pathology, Erasmus Medical Centre Rotterdam, P.O. Box 2040, Rotterdam, 3000, CA, the Netherlands.
- Academic Center for Thyroid Disease, Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, P.O. Box 2040, Rotterdam, 3000, CA, the Netherlands.
- Department of Surgical Oncology and Gastrointestinal Surgery, Utrecht Medical Center, Heidelberglaan 100, Utrecht, 3584 CX, the Netherlands.
ORCID-Profile: Frederik A Verburg
Förderung
- KWF Kankerbestrijding
Zitieren
APA
Coerts, H. I., van Kemenade, F. J., van Ginhoven, T. M., Vriens, M. R., Medici, M., Vriens, D., de Keizer, B., & Verburg, F. A. (2026). The malignancy risk of thyroid incidentalomas detected by [18F]FDG PET/CT lower than expected: a nationwide observational study in the Netherlands. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07714-0
Vancouver
Coerts HI, van Kemenade FJ, van Ginhoven TM, Vriens MR, Medici M, Vriens D, et al. The malignancy risk of thyroid incidentalomas detected by [18F]FDG PET/CT lower than expected: a nationwide observational study in the Netherlands. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-025-07714-0
BibTeX
@article{Coerts2026,
author = {Coerts, Hannelore I and van Kemenade, Folkert J and van Ginhoven, Tessa M and Vriens, Menno R and Medici, M and Vriens, D and de Keizer, Bart and Verburg, Frederik A},
title = {The malignancy risk of thyroid incidentalomas detected by [18F]FDG PET/CT lower than expected: a nationwide observational study in the Netherlands},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
doi = {10.1007/s00259-025-07714-0}
}
EUVIMED